Seoul, Oct 22 (IANS) Samsung Biologics on Tuesday said it has signed a deal worth $1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm.
The deal will last until the end of 2037, the company said in a regulatory filing. Other details remained undisclosed under a confidentiality agreement, Yonhap news agency reported.
Samsung Biologics said the deal reached almost half of the value of its combined manufacturing deals for last year at 3.5 trillion won ($2.53 billion).
So far this year, Samsung Biologics has secured nine deals worth a combined 4.36 trillion won with global biopharmaceutical companies.
In the second quarter, announced in July, the company’s consolidated revenue reached 1.16 trillion won, while operating profit stood at 434.5 billion won. On a standalone basis, the company achieved a revenue of 810.2 billion won, while operating profit came to 329.2 billion won during the same period.
According to the company, the results were driven by the full utilisation of Plants 1 through 3 and the ramp-up of Plant 4 operations.
Samsung Biologics also secured contracts with global pharma, partnering with 16 of the top 20 global pharma companies. The company’s cumulative contract volume surpassed $13 billion as of June.
In line with the company’s commitment and vision to innovation and growth, Samsung Biologics continued to make strategic investments in diverse modalities.
The first half of 2024 saw consolidated revenue of 2.1 trillion won and an operating profit of 655.8 billion won, the company said.
Its Plant 5, expected to be operational by April 2025, will enable the company to provide additional capacity to deliver timely client services.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
